+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Liver Diseases Therapeutics Market by Disease Type, Therapy Type, Drug Class, Route of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Liver Diseases Therapeutics Market by Disease Type, Therapy Type, Drug Class, Route of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Liver Diseases Therapeutics Market by Disease Type, Therapy Type, Drug Class, Route of Administration, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 191 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904957
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Liver Diseases Therapeutics Market is undergoing significant transformation as clinical innovation and regulatory shifts reshape the treatment landscape for liver disorders worldwide. Senior decision-makers must navigate evolving therapies, regional market dynamics, and policy factors to stay ahead in this competitive sector.

Market Snapshot: Liver Diseases Therapeutics Market

The Liver Diseases Therapeutics Market grew from USD 18.12 billion in 2024 to USD 19.64 billion in 2025 and is expected to reach USD 29.06 billion by 2030 with a CAGR of 8.19%. This robust growth reflects heightened demand for targeted solutions to address a wide spectrum of liver diseases globally. The sector’s expansion is driven by advances in molecular biology, immunotherapy, and precision medicine, resulting in improved yet variable patient outcomes across disease types and regions.

Scope & Segmentation

This report delivers comprehensive analysis across disease types, therapy modalities, drug classes, and regional markets, empowering stakeholders to optimize R&D, commercialization, and policy strategies.

  • Disease Types: Alcoholic Liver Disease, Hepatitis B, Hepatitis C, Liver Cancer (Cholangiocarcinoma, Hepatocellular Carcinoma), Nonalcoholic Fatty Liver Disease (Nonalcoholic Steatohepatitis, Simple Steatosis)
  • Therapy Types: Biologics (Monoclonal Antibody, Recombinant Protein), Cell Therapy (CAR T, Stem Cell), Small Molecule
  • Drug Classes: Antifibrotic, Chemotherapeutic, Interferon, Monoclonal Antibody, NS5A Inhibitors (Daclatasvir, Ledipasvir), Nucleoside Analogs (Entecavir, Tenofovir), Protease Inhibitors (Paritaprevir, Simeprevir)
  • Routes of Administration: Intravenous, Oral, Subcutaneous
  • Distribution Channels: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
  • End Users: Clinic, Home Care Settings, Hospital
  • Geographic Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (e.g., United Kingdom, Germany, France, Russia, Italy, Spain, U.A.E., Saudi Arabia, South Africa, Nigeria), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Vietnam, Taiwan)
  • Main Companies Profiled: Gilead Sciences, AbbVie, Merck & Co., Bristol-Myers Squibb, Johnson & Johnson, F. Hoffmann-La Roche, Pfizer, Novartis, GlaxoSmithKline, Intercept Pharmaceuticals

Key Takeaways

  • Rapid scientific innovation is shaping treatment paradigms, with targeted and cell therapies creating new standards in liver care.
  • Disease-specific therapies reflect advances such as biologics for fibrogenic pathways, and small molecules for viral hepatitis—improving adaptability for patient needs.
  • Regional heterogeneity requires strategy customization, as infrastructure and reimbursement models differ widely between the Americas, EMEA, and Asia-Pacific, influencing market penetration and patient access.
  • Strategic alliances, especially with academic centers and advocacy groups, are critical for pipeline de-risking and expediting regulatory approval in competitive markets.
  • Distribution model diversification—across hospital, retail, and online channels—supports improved adherence and wider reach for both acute and chronic disease management.

Tariff Impact

Recent US tariff policies have increased cost pressures on manufacturers by raising import duties for active pharmaceutical ingredients and finished products critical to liver therapeutics. This has led to shifts in sourcing, renewed focus on domestic production, and adjustments in R&D expenditure. Companies are mitigating supply disruption risks through technology transfer, local manufacturing partnerships, and proactive engagement with policy stakeholders. These measures allow agile response to evolving trade environments and support continued drug access.

Methodology & Data Sources

Findings are grounded in a rigorous methodology that combines primary interviews with key opinion leaders, quantitative surveys among healthcare professionals, and comprehensive review of peer-reviewed literature, clinical trial registries, and regulatory filings. This approach ensures robust triangulation and continuous validation of market insights.

Why This Report Matters

  • Enables leadership to anticipate market shifts and align R&D investment with future therapeutic needs in liver disease care.
  • Equips commercial strategists to tailor go-to-market and reimbursement tactics for diverse regional contexts and regulatory settings.
  • Supports investors and stakeholders in identifying new partnership and portfolio expansion opportunities tied to emerging therapies and regional trends.

Conclusion

The outlook for the Liver Diseases Therapeutics Market is defined by ongoing innovation, changing market access dynamics, and the need for strategic agility. Comprehensive, reliable intelligence will support senior leaders in making informed decisions and driving meaningful impact in liver care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Surge in the incidences of liver diseases worldwide
5.1.1.2. Increasing government and private organizations initiatives toward awareness and vaccination programs
5.1.1.3. Changing lifestyles such as consumption of alcohol and smoking
5.1.2. Restraints
5.1.2.1. Concerns over probable side effects of the medication
5.1.3. Opportunities
5.1.3.1. Ongoing research and development activities for prevention and cure of liver diseases
5.1.3.2. Increasing patent expiration of therapeutics
5.1.4. Challenges
5.1.4.1. Strict government regulations and high cost involved in R&D
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Liver Diseases Therapeutics Market, by Treatment
6.1. Introduction
6.2. Anti Viral Drugs
6.3. Chemotherapy Drugs
6.4. Corticosteroids
6.5. Immunoglobulin
6.6. Immunosuppressant Drugs
6.7. Targeted Therapy
7. Liver Diseases Therapeutics Market, by End User
7.1. Introduction
7.2. Ambulatory Surgery Centers
7.3. Hospitals
8. Americas Liver Diseases Therapeutics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Liver Diseases Therapeutics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Liver Diseases Therapeutics Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. LIVER DISEASES THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. LIVER DISEASES THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 7. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 9. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 11. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 13. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. LIVER DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 19. LIVER DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. LIVER DISEASES THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. LIVER DISEASES THERAPEUTICS MARKET DYNAMICS
TABLE 7. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTI VIRAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANT DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 20. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 21. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 22. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 23. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 24. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 25. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 26. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 27. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 28. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 29. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 30. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 31. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 32. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 34. AUSTRALIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 35. AUSTRALIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 37. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 39. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. INDONESIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 41. INDONESIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. JAPAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 43. JAPAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 44. MALAYSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 45. MALAYSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. PHILIPPINES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 47. PHILIPPINES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. SINGAPORE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 49. SINGAPORE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. SOUTH KOREA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 51. SOUTH KOREA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. TAIWAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 53. TAIWAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. THAILAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 55. THAILAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. VIETNAM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 57. VIETNAM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 59. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 61. DENMARK LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 62. DENMARK LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. EGYPT LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 64. EGYPT LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. FINLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 66. FINLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 67. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 68. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 70. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. ISRAEL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 72. ISRAEL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 74. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. NETHERLANDS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 76. NETHERLANDS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. NIGERIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 78. NIGERIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. NORWAY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 80. NORWAY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. POLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 82. POLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. QATAR LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 84. QATAR LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 86. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. SAUDI ARABIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 88. SAUDI ARABIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. SOUTH AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 90. SOUTH AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 92. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. SWEDEN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 94. SWEDEN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. SWITZERLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 96. SWITZERLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. TURKEY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 98. TURKEY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. UNITED ARAB EMIRATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 100. UNITED ARAB EMIRATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. LIVER DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 104. LIVER DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Liver Diseases Therapeutics market report include:
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Novartis AG
  • GlaxoSmithKline plc
  • Intercept Pharmaceuticals, Inc.

Table Information

Report AttributeDetails
No. of Pages191
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 19.64 Billion
Forecasted Market Value ( USD ) by 2030 $ 29.06 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Liver Disease Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Antiviral Drugs, Vaccines), By Disease (Hepatitis, Autoimmune Diseases, Cancer), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Liver Disease Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Antiviral Drugs, Vaccines), By Disease (Hepatitis, Autoimmune Diseases, Cancer), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Liver Disease Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Liver Disease Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Non-Alcoholic Fatty Liver Disease Therapeutics - Global Strategic Business Report - Product Image

Non-Alcoholic Fatty Liver Disease Therapeutics - Global Strategic Business Report

  • Report
  • 186 Pages
  • Global
From
Chronic Liver Diseases Therapeutics Global Market Report 2025 - Product Image

Chronic Liver Diseases Therapeutics Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Insight, 2025 - Product Image

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Insight, 2025

  • Clinical Trials
  • 240 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.